IN2014MN01795A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01795A
IN2014MN01795A IN1795MUN2014A IN2014MN01795A IN 2014MN01795 A IN2014MN01795 A IN 2014MN01795A IN 1795MUN2014 A IN1795MUN2014 A IN 1795MUN2014A IN 2014MN01795 A IN2014MN01795 A IN 2014MN01795A
Authority
IN
India
Prior art keywords
patient
biological fluid
percentage
bcl2l10 protein
sample
Prior art date
Application number
Inventor
Thomas Cluzeau
Patrick Auberger
Guillaume Robert
Frédéric Luciano
Original Assignee
Université Nice Sophia Antipolis
Ct Hospitalier Universitaire Nice
Inst Nat Santé Et De La Rech Médicale Inserm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Nice Sophia Antipolis, Ct Hospitalier Universitaire Nice, Inst Nat Santé Et De La Rech Médicale Inserm filed Critical Université Nice Sophia Antipolis
Publication of IN2014MN01795A publication Critical patent/IN2014MN01795A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

The invention relates to an analysis method for predicting resistance to azacitidine treatment in a patient using the BCL2L10 protein contained in a sample of biological fluid taken from said patient and also biological molecules which specifically bind the BCL2L10 protein. It is characterized in that a sample of biological fluid is recovered from a patient; the percentage of total cells in said biological fluid expressing the BCL2L10 protein is calculated; this calculated percentage is compared with a reference threshold value this threshold value being between 20% and 60%; and resistance to azacitidine treatment is diagnosed in a patient who has a percentage of cells expressing the BCL2L10 protein in said biological fluid which is greater than said reference value.
IN1795MUN2014 2012-02-28 2013-02-28 IN2014MN01795A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1200584A FR2987446B1 (en) 2012-02-28 2012-02-28 DIAGNOSTIC TEST FOR RESISTANCE TO AZACITIDINE
PCT/FR2013/000055 WO2013128089A1 (en) 2012-02-28 2013-02-28 Test for diagnosing resistance to azacitidine

Publications (1)

Publication Number Publication Date
IN2014MN01795A true IN2014MN01795A (en) 2015-07-03

Family

ID=48083449

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1795MUN2014 IN2014MN01795A (en) 2012-02-28 2013-02-28

Country Status (11)

Country Link
US (1) US20150094217A1 (en)
EP (1) EP2820417A1 (en)
JP (1) JP6273552B2 (en)
CN (1) CN104321649A (en)
AU (1) AU2013224832A1 (en)
BR (1) BR112014021173A2 (en)
CA (1) CA2865684A1 (en)
FR (1) FR2987446B1 (en)
IL (1) IL234332A0 (en)
IN (1) IN2014MN01795A (en)
WO (1) WO2013128089A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638400T3 (en) * 2014-03-27 2017-10-20 Palacky University, Olomouc Method of predicting tumor response to DNA methylation inhibitors and alternative therapeutic regimens to overcome resistance
FR3048698B1 (en) * 2016-03-11 2021-03-05 Univ Claude Bernard Lyon BCL2 L10 INTERACTION INHIBITORS / IP3 RECEIVER
WO2019077080A1 (en) * 2017-10-19 2019-04-25 Universite Claude Bernard Lyon 1 Evaluation of the risk of metastatic relapse in breast cancer patients
CN114874987A (en) * 2022-03-01 2022-08-09 洛阳市中心医院（郑州大学附属洛阳中心医院） Myelodysplastic syndrome drug-resistant cell model and construction method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078100A1 (en) * 2004-02-13 2005-08-25 Bml, Inc. Method of detecting cancer cell acquiring drug-resistance
EP1737980A2 (en) * 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
CN101632643A (en) * 2009-08-18 2010-01-27 杭州咸达医药科技有限公司 Azacitidine freeze-drying powder injection and preparation method thereof
JP5190477B2 (en) * 2010-02-22 2013-04-24 譲治 稲澤 Method for detecting lung cancer cells that have acquired drug resistance to camptothecins against anticancer drugs
PT2576825T (en) * 2010-05-27 2018-02-02 Inst Nat Sante Rech Med Methods for assessing endometrium receptivity of a patient

Also Published As

Publication number Publication date
AU2013224832A1 (en) 2014-10-16
IL234332A0 (en) 2014-10-30
AU2013224832A8 (en) 2014-11-13
CA2865684A1 (en) 2013-09-06
EP2820417A1 (en) 2015-01-07
WO2013128089A1 (en) 2013-09-06
US20150094217A1 (en) 2015-04-02
JP6273552B2 (en) 2018-02-07
FR2987446B1 (en) 2016-01-01
JP2015513369A (en) 2015-05-11
BR112014021173A2 (en) 2017-08-22
CN104321649A (en) 2015-01-28
FR2987446A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
ZA201604468B (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
IL246060A0 (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
PL2986735T3 (en) Method for identifying the quantitative composition of blood cells in a sample
WO2012149493A3 (en) Hsp90 combination therapy
PH12013500544A1 (en) Breast cancer diagnostics
WO2012122564A3 (en) Diagnostic and sample preparation devices and methods
WO2012094580A3 (en) Compounds that modulate oxidative stress
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
MX2022013625A (en) Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota.
ZA201402460B (en) Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly
HUE043360T2 (en) Container for determining of analytes and/or chemico-physical parameters, as well as determining of urinary sediment, in urine; and method of full urine analysis using this container
HK1254030A1 (en) Methods of treating autoimmune and alloimmune disorders
MX358997B (en) Method for evaluating blood coagulation reaction.
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
IN2014MN01795A (en)
MX2021009528A (en) Rgma fragment based diagnostic assay.
SG11201700876RA (en) Methods and compositions for analyzing glucose-6-phosphate dehydrogenase activity in blood samples
MX2019008005A (en) Methods and compositions for diagnosing preeclampsia.
WO2012131092A3 (en) Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
WO2012144784A3 (en) Monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof
WO2011141153A8 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
WO2014198670A3 (en) Methods of viewing and analyzing high content biological data